ADAP News

14 companies were scheduled to go public this week, including 10 health care deals. Only 8 IPOs got through, as 3 biotechs have been pushed back to next week, two companies postponed and one withdrew. however; IPO investors had plenty of options while the NASDAQ composite hit a 1-month low. This week's deals did include the year's largest IPO so far and the first restaurant chain...read more

Adaptimmune Therapeutics, which is developing cancer immunotherapies using genetically enhanced T-cell receptors, raised $191 million by offering 11.3 million shares at $17, at high end of the $15-$17 range. At its offer price, Adaptimmune Therapeutics will command a fully diluted market cap at $1.3 billion. The company will list on the NASDAQ under the symbol ADAP. BofA Merrill...read more

This could be the busiest 5-day stretch in the IPO market since the week of July 28, 2014, as 14 companies look to raise nearly $2 billion. However, last week's mediocre returns suggest that ...read more

Adaptimmune Therapeutics, which is developing cancer immunotherapies based on genetically engineered T-cell receptors, announced terms for its IPO on Monday. The Abingdon, United Kingdom-based company plans to raise $150 million by offering 9.4 million shares at a price range of $15 to $17. At the midpoint of the proposed range, Adaptimmune Therapeutics would command a fully diluted...read more